Copertina

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kunhee Kim, Seung Hyuk Yim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Jun Yong Park, Sang Hoon Ahn, Deok‐Gie Kim, Hye Won Lee
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
di: Amy Sangam, et al.
Pubblicazione: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
di: Mathias Jachs, et al.
Pubblicazione: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
di: Seogsong Jeong, et al.
Pubblicazione: (2026)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
di: Yanxue Lin, et al.
Pubblicazione: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
di: Soon Sun Kim, et al.
Pubblicazione: (2025)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
di: Richie Manikat, et al.
Pubblicazione: (2024)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
di: Eunice Yewon Lee, et al.
Pubblicazione: (2024)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
di: Kyuwon Kim, et al.
Pubblicazione: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
di: Hye Won Lee, et al.
Pubblicazione: (2024)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
di: Muhammad Osama, et al.
Pubblicazione: (2024)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
di: Wah Loong Chan, et al.
Pubblicazione: (2024)

Diagnostic Value of MR Elastography and MRI‐Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology
di: Eun‐Ki Min, et al.
Pubblicazione: (2026)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
di: Donghee Kim, et al.
Pubblicazione: (2025)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
di: Donghee Kim, et al.
Pubblicazione: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
di: Romeo Kuo‐Cheng Wu, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
di: Qiong Yi, et al.
Pubblicazione: (2024)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
di: Benedikt Simbrunner, et al.
Pubblicazione: (2025)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
di: Derek D. Satre, et al.
Pubblicazione: (2024)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
di: Paul Y. Kwo, et al.
Pubblicazione: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
di: Beom Kyung Kim
Pubblicazione: (2025)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
di: Chien‐Wei Su
Pubblicazione: (2026)

Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis
di: Maya Fischman, et al.
Pubblicazione: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Gian Paolo Caviglia, et al.
Pubblicazione: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
di: Ming Liu, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
di: Yixuan Zhu, et al.
Pubblicazione: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
di: Danny Con
Pubblicazione: (2025)

Editorial: Another brick in the CDST wall: Authors' reply
di: Kyuwon Kim, et al.
Pubblicazione: (2024)